Oxis Establishes Development Partnership with Altor Bioscience

Oxis International (OTCQB:OXIS) will develop a 161533 TriKE fusion protein for cancer therapies using its trispecific killer engager technology, in partnership with Altor BioScience.
As quoted in the press release:

Altor, based in Miramar, Fla., is a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases. Altor is run by Hing C. Wong, Ph.D., Founder and Chief Executive Officer and Chaired by Dr. Patrick Soon-Shiong, a noted cancer researcher who owns NantWorks, a network of healthcare companies.
The TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. As demonstrated in non-clinical models, this targeted immunotherapy directs immune cells to kill cancer cells while diminishing drug-related toxicity. Addition of Altor’s IL-15 superagonist technology to the 161533 TriKE molecule would further augment its ability to stimulate immune responses.
Under the partnership, Oxis and Altor will conduct a first-in-man Phase 1 FDA human clinical trial of the 161533 TriKE for the treatment of hematologic malignancies.

Click here to read the full press release.

Source: www.accesswire.com